Clinical trials: PAH
Pulmonary Arterial Hypertension
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT04712669
- Testing
- rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 108 people
- Sponsor
- Altavant Sciences GmbH
High Altitude, Healthy
Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Healthy Individuals
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy…
- Conditions
- High Altitude, Healthy, Healthy Adult, High Altitude Effects
- Trial name
- NCT07804589
- Testing
- Re-Ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Congenital Heart Disease, Cardiomyopathy
Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease
The goal of this observational study, drug-free, cross-sectional, single-center is to describe the incidence and characteristics of the clinical course and any short- and medium-term complications of patients with congenital…
- Conditions
- Congenital Heart Disease, Cardiomyopathy, Pulmonary Arterial Hypertension, SARS CoV-2 Infection
- Trial name
- NCT06784687
- Where
- Italy
- Volunteers
- 2,376 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Pulmonary Arterial Hypertension
Safety and Efficacy of BIA 5-1058 in PAH
This study aims to assess the safety and tolerability of the individual highest tolerated zamicastat doses, achieved in the study BIA-51058-201, during long-term treatment in Pulmonary Arterial Hypertension (PAH) disease.
- Trial name
- NCT06009185
- Testing
- Oral zamicastat
- Where
- 11 sites in Austria, Germany and 4 more
- Volunteers
- 20 people
- Sponsor
- Bial - Portela C S.A.
Refractory Lupus Nephritis, Systemic Sclerosis
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
- Trial name
- NCT06947460
- Testing
- CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Primary and Secondary Pulmonary Hypertension
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension
- Trial name
- NCT00155714
- Testing
- type-5 phosphodiesterase Inhibitor (Sildenafil)
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Phenylketonurias
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
This is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU).
- Trial name
- NCT06332807
- Testing
- NGGT002
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- NGGT INC.
Pulmonary Arterial Hypertension (PAH)
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy
Pulmonary Arterial Hypertension or PAH is a progressive condition for which there is no cure. Even with substantial pharmacologic advances in the modern treatment era, survival still remains unacceptably poor, as reported in…
- Trial name
- ALPHA (NCT03145298)
- Testing
- Allogeneic Human Cardiosphere-Derived Stem Cells
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Cedars-Sinai Medical Center
Pulmonary Arterial Hypertension (PAH)
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a…
- Trial name
- NCT07759804
- Testing
- LIQ861 (treprostinil) inhalation powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Liquidia Technologies, Inc.
Systemic Sclerosis, Pulmonary Hypertension
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e.
- Trial name
- NCT02243111
- Testing
- Doppler ultrasound
- Where
- Israel
- Volunteers
- 1 people
- Sponsor
- Echosense Ltd.
Pulmonary Arterial Hypertension, Interstitial Lung Disease
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT00705133
- Testing
- Treprostinil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rajan Saggar
Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
What is this study about? This study will test whether adding sotatercept to usual medicines for pulmonary arterial hypertension (PAH) can help adults who have PAH due to unrepaired congenital heart defects (atrial or ventricular…
- Trial name
- SuMILE (NCT07356778)
- Testing
- Sotatercept, vasodilator-based PAH therapy
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Kazuya Hosokawa
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Prognostic Value of the Right Ventricular Function by Portable Ultrasound in Patients With Pulmonary Hypertension.
Pulmonary arterial hypertension (PAH) is a disease characterized by obliteration and remodeling of small-caliber pulmonary arteries, progressively generating an increase in pulmonary vascular resistance, right heart failure, and…
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Cardiac Ultrasound
- Trial name
- NCT05343091
- Testing
- cardiac ultrasound
- Where
- Mexico
- Volunteers
- 62 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Pulmonary Arterial Hypertension
Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs
In this study researchers want to learn more about Pulmonary Arterial Hypertension, a type of high blood pressure in the lungs related to the narrowing of the small blood vessels in the lungs (group 1 according to WHO…
- Trial name
- START (NCT03863990)
- Testing
- PAH medication
- Where
- Argentina
- Volunteers
- 104 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
The objectives of this study are to evaluate the safety of RT234 and the effects of RT234 on exercise capacity as assessed by Cardiopulmonary Exercise Testing (CPET) and six minute walk testing (6MWT) as well as exertional…
- Trial name
- VIPAH-PRN_2B (NCT04266197)
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
- Where
- 26 sites in United States
- Volunteers
- 42 people
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
This single center, open label, randomized, two-period, two-sequence cross-over study is designed to evaluate the relative bioavailability of a treprostinil diethanolamine 1 mg tablet in reference to treprostinil diethanolamine 1…
- Trial name
- NCT01172496
- Testing
- treprostinil diethanolamine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?
Pulmonary Arterial Hypertension is a rare and progressive condition that compromises pulmonary circulation and can lead to right ventricular failure.
- Trial name
- AIRDROP (NCT07457762)
- Testing
- The patients will receive guidance on inhaler use and adherence
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- University of Sao Paulo General Hospital
Hypertension, Pulmonary
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
The purpose of this study is to compare the effects of switching from inhaled Ventavis to intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis therapy.
- Trial name
- NCT00458042
- Testing
- treprostinil sodium
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Phenylketonurias
A Prospective Clinical Study of Phenylketonuria (PKU)
This is a study for adults and children ≥ 14 years old who have Phenylketonuria (PKU) with uncontrolled plasma Phe levels. No clinical intervention or study drug is provided by BioMarin in this study.
- Trial name
- NCT04452513
- Where
- 14 sites in United States
- Volunteers
- 32 people
- Sponsor
- BioMarin Pharmaceutical
Pulmonary Arterial Hypertension
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.
- Trial name
- NCT00323297
- Testing
- Bosentan, Sildenafil Citrate
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 105 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.